Skip to main content
Premium Trial:

Request an Annual Quote

Decode Buys Cancer Research Firm UVS for $5.5M in Stock

NEW YORK, Jan. 18 (GenomeWeb News) - Decode Genetics has bought Urdur, Verdandi, Skuld, a privately held Icelandic cancer research company, to expand its discovery and drug development capabilities based on population genetics, Decode said today.


"UVS has organized cancer research in Iceland since 1998 and has recruited a large number of patients and controls into their studies," said Decode's CEO, Kari Stefansson, in a statement.


Reykjavik-based Decode acquired UVS for $5.5 million in common stock based on the average closing price for the 30 days preceding the acquisition, according to the statement.


Shares of Decode were trading lower in afternoon trade, after hitting a 52-week high yesterday of $10.77.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.